What to Know About This Fund's $140 Million FTI Consulting Bet Amid Rising Demand

Fiduciary Management initiated a new 823,713-share position in FTI Consulting, an estimated $140.52 million purchase that valued the stake at $145.61 million at quarter-end. The filing signals a contrarian vote of confidence as FTI shares were down about 10% over the past year, even as Q1 revenue rose 9.5% year over year to $983.3 million and full-year guidance was reaffirmed. Margin pressure remains a watch item, with adjusted EBITDA margin slipping to 9.8% from 12.8% a year ago.

Analysis

This looks less like a simple endorsement of FCN and more like a signal that the market may be mispricing the durability of countercyclical demand. The setup is attractive because the business is levered to complexity: if restructuring, litigation, and strategic review activity stay elevated, earnings can remain resilient even if broader consulting budgets soften. The key second-order effect is that weaker share performance can itself attract capital from quality-oriented allocators hunting for “out-of-favor compounders,” which can extend valuation support beyond the next quarter.

The margin compression is the real tell. Revenue growth is not the issue; the risk is that FCN is entering a phase where compensation inflation and delivery mix offset top-line momentum, so the stock can work only if investors believe current margin pressure is temporary rather than structural. If operating leverage does not re-accelerate over the next 2-3 quarters, the market will likely cap multiple expansion even with intact guidance. In that scenario, downside is less about a demand collapse and more about FCN becoming a “good business, fair stock” at current levels.

Competitively, the strongest implication is that firms with deeper restructuring benches and faster utilization recovery should keep taking share from generalist advisory shops when corporate stress rises. That favors names with recurring complex-event exposure over cyclically exposed advisory franchises, and it also argues that FCN’s medium-term upside is tied to a sustained macro backdrop of higher rates, refinancing pressure, and regulatory friction. The consensus may be underestimating how persistent those tailwinds can be if capital markets remain selective into year-end.

The contrarian angle is that the recent weakness may already discount the margin risk, while the revenue trajectory still reflects a favorable demand regime. If the company proves it can hold EBITDA margins near current levels while growing low-double digits, the stock could re-rate quickly over the next 6-12 months. The cleanest signal to watch is not the top line, but whether compensation discipline and utilization improve by the next two reporting cycles.

Key Decisions for Investors

• Go long FCN on weakness over the next 1-2 weeks, but size as a tactical position: reward is a re-rating toward prior multiple bands if margins stabilize; risk is another quarter of EBITDA margin compression that stalls the stock.
• Pair trade: long FCN / short a more generalist business-services or advisory name with lower complexity exposure over 3-6 months; the thesis is that FCN’s countercyclical mix should hold up better if corporate stress persists.
• Use FCN Jan-2027 calls instead of outright stock if implied vol is not excessive; this captures a 6-12 month multiple expansion scenario while limiting drawdown if margin pressure lingers.
• Set a stop on FCN if the next earnings print shows continued margin erosion without acceleration in restructuring-related revenue; that would signal the market’s concerns are structural, not temporary.
• Monitor BKNG and SCHW only as indirect sentiment signals: if quality allocators continue favoring these large-cap compounders, FCN may remain a secondary target for factor-driven accumulation rather than fundamental sponsorship.